iSpecimen Inc 10-Q for FY2026 Q1
iSpecimen Inc. (ISPC)
About this 10-Q
iSpecimen Inc filed this 10-Q on May 18, 2026, covering the quarter ended March 31, 2026 (FY2026 Q1).
Headline figures
Quarter ended March 31, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $156.01K
- down 85.2% from $1.06M a year earlier
- Net loss
- $2.28M
- compared with a net loss of $1.66M a year earlier
- Diluted EPS
- -$6.66
- compared with -$28.55 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For
the Quarterly Period Ended
For the transition period from to
Commission
File No.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| The |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| ☒ | Smaller reporting company | |||
| Emerging growth company | ||||
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of May 15, 2026, there were
iSPECIMEN INC.
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026
TABLE OF CONTENTS
i
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
iSpecimen Inc.
Condensed Balance Sheets
March 31, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable and other receivables, net of allowance for doubtful accounts of $ | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Internally developed software, net | ||||||||
| Intangible assets under development | ||||||||
| Operating lease right-of-use asset | ||||||||
| Security deposits | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Operating lease current obligation | ||||||||
| Deferred revenue | ||||||||
| Total current liabilities | ||||||||
| Operating lease long-term obligation | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (See Note 9) | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, $ | ||||||||
| Series C convertible preferred stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| ( | ) | ( | ) | |||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
See accompanying notes to these unaudited condensed financial statements.
1
iSpecimen Inc.
Condensed Statements of Operations and Comprehensive Loss
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | $ | ||||||
| Operating expenses: | ||||||||
| Cost of revenue | ||||||||
| Technology | ||||||||
| Sales and marketing | ||||||||
| Supply development | ||||||||
| Fulfillment | ||||||||
| General and administrative | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expense), net | ||||||||
| Interest expense | ( | ) | ||||||
| Interest income | ||||||||
| Interest and penalties on sales tax liability | ( | ) | ( | ) | ||||
| Other income (expense), net | ( | ) | ||||||
| Total other income (expense), net | ( | ) | ||||||
| Net loss and comprehensive loss | $ | ( | ) | $ | ( | ) | ||
| Net loss per share - basic and diluted | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares of common stock outstanding - basic and diluted | ||||||||
See accompanying notes to these unaudited condensed financial statements.
Reflects retroactive effect of a 1-for-40 reverse stock split on April 27, 2026.
2
iSpecimen Inc.
Condensed Statements of Changes in Stockholders’ Equity
(Unaudited)
| Three Months Ended March 31, 2026 | ||||||||||||||||||||||||||||||||||||||||
| Accumulated | ||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Total | ||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Treasury Stock | Paid-In | Comprehensive | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | | ||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | |||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock | — | — | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock through exercise of prefunded warrants | — | ( | ) | |||||||||||||||||||||||||||||||||||||
| Issuance of common stock through conversion of Series C convertible preferred stock | ( | ) | ( | ) | — | ( | ) | — | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||
See accompanying notes to these unaudited condensed financial statements.
Reflects retroactive effect of a 1-for-40 reverse stock split on April 27, 2026.
3
iSpecimen Inc.
Condensed Statements of Changes in Stockholders’ Equity
(Unaudited)
| Three Months Ended March 31, 2025 | ||||||||||||||||||||||||||||||||||||||||
| Accumulated | ||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Total | ||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Treasury Stock | Paid-In | Comprehensive | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | | ||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | |||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock | — | |||||||||||||||||||||||||||||||||||||||
| Issuance of common stock through exercise of prefunded warrants | — | ( | ) | — | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||
See accompanying notes to these unaudited condensed financial statements
4
iSpecimen Inc.
Condensed Statements of Cash Flows
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | ||||||||
| Amortization of internally developed software | ||||||||
| Amortization of other intangible assets | ||||||||
| Depreciation of property and equipment | ||||||||
| Bad debt expense | ||||||||
| Gain on debt settlement | ( | ) | ||||||
| Accounts receivable | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Operating lease right-of-use asset | ||||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses | ( | ) | ||||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITY: | ||||||||
| Capitalization of internally developed software | ( | ) | ||||||
| Net cash used in investing activity | ( | ) | ||||||
| Net decrease in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
See accompanying notes to these unaudited condensed financial statements.
5
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Business
iSpecimen
Inc. (“iSpecimen” or the “Company”) was incorporated in 2009 under the laws of the state of Delaware. The Company
has developed and launched a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples,
and data, with hospitals, laboratories, and other organizations who have access to them. iSpecimen is a technology-driven company founded
to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells (“biospecimens”)
for their research, with biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. The iSpecimen
Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.
The Company is headquartered in Woburn, Massachusetts and its principal market is North America. The Company operates as
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) as determined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for interim financial information, and, pursuant to the rules and regulations of Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”), published by the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. They may not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Reverse Stock Split
On
October 9, 2023, the Company received a notification from Nasdaq that its Common Stock failed to maintain a minimum bid price of $
On
July 19, 2024, the Company’s stockholders approved a proposal to amend the Company’s Fourth Amended and Restated Certificate
of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s issued and outstanding
shares of common stock, as well as any shares of common stock held by the Company in treasury, at a ratio in the range from
On
August 19, 2024, the Company’s board of directors approved a one-for-twenty (
On
October 1, 2024, the Company received a notification from Nasdaq that the Staff has determined that for the last
Except
as otherwise indicated, all references to the Company’s common stock, share data, per share data and related information has been
adjusted for the Reverse Stock Split ratio of 1-for-20 as if they had occurred at the beginning of the earliest period presented. The
Reverse Stock Split combined each
Subsequent to March 31, 2026, the Company implemented a 1-for-40 Reverse Stock Split on its common shares. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares resulting from the Reverse Stock Split were rounded to the nearest whole number. All share and per share data in these financial statements have been retroactively restated to reflect the effect of the reverse stock split.
6
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Going Concern Uncertainty and Management’s Plan
The
Company has recognized recurring losses since inception. As of March 31, 2026, the Company had negative working capital of $
The
future success of the Company is dependent on its ability to successfully obtain additional working capital and/or to ultimately attain
profitable operations. During the three months ended March 31, 2026, the Company continued its efforts, which had begun in 2023, to decrease
its capital and operational expenditures by cutting costs and right sizing the Company through a reduction in workforce while streamlining
operations and rationalizing resources to focus on key market opportunities. The reductions in workforce since January 1, 2024 through
December 31, 2025, cumulatively resulted in an estimated reduction in monthly compensation costs of approximately
The Company may be unsuccessful in increasing its revenues or contain its operating expenses, or it may be unable to raise additional capital on commercially favorable terms. The Company’s failure to generate additional revenues or contain operating costs would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue as a going concern. If the Company does not generate enough revenue to provide an adequate level of working capital, its business plan will be scaled down further.
These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued. Management’s plan to mitigate the conditions that raise substantial doubt includes generating additional revenues, deferring certain projects and capital expenditures and eliminating certain future operating expenses for the Company to continue as a going concern. However, there can be no assurance that the Company will be successful in completing any of these options. As a result, management’s plans cannot be considered probable and thus do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company’s significant accounting policies and recent accounting standards are summarized in Note 2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. There were no significant changes to these accounting policies during the three months ended March 31, 2026.
7
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Use of Estimates
The preparation of the Company’s unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the deferred tax valuation allowances, revenue recognition, stock-based compensation, allowance for doubtful accounts, accrued expenses, and the useful lives of internally developed software and sequenced data. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Concentrations of Credit Risk - Suppliers
For
the three months ended March 31, 2026, one supplier (Supplier A) accounted for approximately
The Company sources certain specimen types and related services from a limited number of suppliers. The loss of any of the significant suppliers described above, or a disruption or reduction in the volume of specimens or services they provide, could adversely affect the Company’s ability to fulfill customer orders on a timely basis and could have a material adverse effect on the Company’s business, financial condition, and results of operations.
Investments
The Company’s investments are considered to be available-for-sale and are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive income. Purchases and sales of securities are reflected on a trade-date basis. Realized gains or losses are released from accumulated other comprehensive income and into earnings on the statement of operations, and amortization of premiums and accretion of discounts on the U.S treasury bills are recorded in interest expense or income, respectively.
The Company continually monitors the difference between its cost basis and the estimated fair value of its investments. The Company’s accounting policy for impairment recognition requires other-than-temporary impairment charges to be recorded when it determines that it is more likely than not that it will be unable to collect all amounts due according to the contractual terms of the fixed maturity security or that the anticipated recovery in fair value of the equity security will not occur in a reasonable amount of time. Impairment charges on investments are recorded based on the fair value of the investments at the measurement date or based on the value calculated using a discounted cash flow model. Credit-related impairments on fixed maturity securities that the Company does not plan to sell, and for which it is not more likely than not to be required to sell, are recognized in net income. Any non-credit related impairment is recognized as a component of other comprehensive income. Factors considered in evaluating whether a decline in value include: the length of time and the extent to which the fair value has been less than cost; the financial condition and near-term prospects of the issuer; and the likelihood that it will be required to sell the investment.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:
| ● | Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets. |
| ● | Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. |
| ● | Level 3 — Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. |
For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate their fair values as of March 31, 2026 and December 31, 2025, respectively, because of their short-term nature.
8
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Revenue Recognition and Accounts Receivable
The Company recognizes revenue using the five-step approach as follows: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the Company satisfies the performance obligations.
The Company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites, for the Company’s customers using the Company’s proprietary software, the iSpecimen Marketplace, to identify, locate, and ultimately validate the required specimens to the Company’s customers’ requested specifications. The Company’s performance obligation is to procure a specimen meeting the customer’s specification(s) from a supplier, on a “best efforts” basis, for the Company’s customer at the agreed price per specimen as indicated in the customer’s contract with the Company. The Company does not currently charge suppliers or customers for the use of the Company’s proprietary software. Each customer will execute a material and data use agreement with the Company or agree to online purchase terms, each of which includes terms such as specimen and data use, shipment terms, payment, and cancellation terms. These are then supplemented by purchase orders that specify specimen requirements including detailed inclusion/exclusion criteria, quantities to be collected, and pricing. Collectively, these customer agreements represent the Company’s contracts with its customers. Generally, contracts have fixed unit pricing. For certain specimen orders, a refundable customer deposit may be required prior to order fulfillment depending on project set-up requirements, which is presented as deferred revenue. The Company expects to recognize the deferred revenue as revenue when the Company performs its service obligation.
Specimen collections occur at supply sites within the Company’s network. “Collection” is when the specimen has been removed, or “collected” from the patient or donor. A specimen is often collected specifically for a particular Company order. Once collected, the specimen is assigned by the supplier to the Company and control of the specimen passes to the Company. “Accession” is the process whereby a collected specimen and associated data are registered and assigned in the iSpecimen Marketplace to a particular customer order, which can occur while a specimen is at the supplier site or while at the Company site and it is when control of the specimen passes to the customer. Suppliers may ship specimens to the Company or directly to the customer if specimens must be delivered within a short time period (less than 24 hours after collection) or shipping to the Company is not practical.
The Company has evaluated principal versus agent considerations as part of the Company’s revenue recognition policy. The Company has concluded that it acts as principal in the arrangement as it manages the procurement process from beginning to end and determines which suppliers will be used to fulfill an order, usually takes physical possession of the specimens, sets prices for the specimens, and bears the responsibility for customer credit risk.
The Company recognizes revenue over time, as the Company has created an asset with no alternative use to the Company, which has an enforceable right to payment for performance completed to date. At contract inception, the Company reviews a contract and related order upon receipt, to determine if the specimen ordered has an alternative use by the Company. Generally, specimens ordered do not have an alternative future use to the Company and the performance obligation is satisfied when the related specimens are delivered. In the rare circumstances where specimens do have an alternative future use, the Company’s performance obligation is satisfied at the time of shipment.
Customers are generally invoiced upon shipment. Depending on the quantity of specimens ordered, it may take several accounting periods to completely fulfill a purchase order. In other words, there can be multiple invoices issued for a single purchase order, reflecting the specimens being delivered over time.
Once a specimen that has no alternative future use and for which the Company has an enforceable right to payment, has been accessioned, the Company records the offset to revenue in accounts receivable – unbilled. Once the specimen has been shipped and invoiced, a reclassification is made from accounts receivable - unbilled to accounts receivable.
Customers are generally given days from the receipt of specimens to inspect the specimens to ensure compliance with specifications set forth in the purchase order documentation. Customers are entitled to either receive replacement specimens or receive reimbursement of payments made for such specimens. The Company has a nominal history of returns for nonacceptance of specimens delivered. When this occurs, the Company gives the customer a credit for the returns. The Company has not recorded a returns allowance.
9
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Significant customers
For
the three months ended March 31, 2026, one customer (Customer A) accounted for approximately
As
of March 31, 2026, one customer accounted for
The loss of any of the customers described above, a significant reduction in their purchases, or difficulties collecting outstanding amounts due from these customers could have a material adverse effect on the Company’s business, financial condition, and results of operations.
The following table summarizes the Company’s revenue for the three months ended March 31, 2026 and 2025:
| Three months ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Specimens - contracts with customers | $ | $ | ||||||
| Shipping and other | ||||||||
| Revenue | $ | $ | ||||||
The
Company carries its accounts receivable at the invoiced amount less an allowance for doubtful accounts. On a periodic basis, the Company
evaluates its accounts receivable to determine if an allowance for doubtful accounts is necessary, based on the current expected credit
loss model. Receivables are written off when deemed uncollectible, with any future recoveries recorded as income when received. As of
March 31, 2026 and December 31, 2025, the Company had an allowance for doubtful accounts of $
The Company applies the practical expedient to account for shipping and handling activities as fulfillment cost rather than as a separate performance obligation. Shipping and handling costs incurred are included in cost of revenue.
Since 2024, the Company recognized its revenue when the related specimens are delivered.
Internally Developed Software, Net
The
Company capitalizes certain internal and external costs incurred during the application development stage of internal-use software projects
until the software is ready for its intended use. Amortization of the asset commences when the software is complete and placed into service
and is recorded in operating expenses. The Company amortizes completed internal-use software over its estimated useful life of
Intangible assets under development
During
the year 2025, the Company internally develop its AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process
of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network. The Company
paid $
The Company performs the impairment test on an annual basis, or when events or changes in circumstances indicate that its carrying value may not be recoverable, and an impairment loss shall be recognized if the carrying amount of the intangible assets are not recoverable and its carrying amount exceeds its fair value.
10
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Other Intangible Assets, Net
The
Company procures data generated from sequencing of Formalin-Fixed Paraffin-Embedded (“FFPE”) blocks from a third-party sequencer
which the Company licenses to its customers with the sale of FFPE blocks at an additional cost. The sequenced data is also organized
to form a database of research content that is available for sale through a subscription model. The Company has determined that the sequenced
data is an intangible asset and capitalizes the cost to procure the sequenced data. The sequenced data is amortized to cost of revenue
over an estimated useful life of
Impairment of Long-Lived Assets
Management reviews long-lived assets for impairment when circumstances indicate the carrying amount of an asset may not be recoverable. An impairment loss is recognized when expected cash flows are less than the asset’s carrying value. Long-lived assets consist of property and equipment, internal-use software and other intangible assets. impairment charges were recorded for the three months ended March 31, 2026 and 2025.
Inventory
The Company does not speculatively purchase and bank samples in anticipation of future, unspecified needs. The Company procures specimens from its suppliers and distributes specimens to its Customers after they obtain an order for specimens from a research client. Therefore, the Company does not take possession of or inspect the quality of the specimens, given that they are shipped directly from the supply site. For this reason, the Company does not have a substantive inventory risk. However, whenever delivered specimens do not meet the specifications required by the Customers, these specimens are returned as per the Company’s return policy or discarded for replacement. The Company capitalizes the costs of all returned and rejected specimens that were not requested for replacements.
As
at December 31, 2024, the inventory consists of several types of human biospecimens – biofluids (plasma/serum) and solid tissues
(blocks/curls). During the year ended December 31, 2025, the Company capitalized net additional costs of approximately $
Management reviews inventory assets for impairment when circumstances indicate the carrying amount of an asset may not be recoverable. During the year ended December 31, 2025, the Company performs the impairment test and concluded that an impairment loss must be recognized because most of the remaining specimens are obsolete and that those returned specimens are very difficult to sell to other Customers and are deemed no longer recoverable. The Company recorded for the impairment as inventory reserve.
Debt Issuance Costs
Debt issuance costs are recorded net against the related debt and amortized to interest expense over the life of the related debt.
Stock-Based Compensation
The Company records stock-based compensation for options granted to employees, non-employees, and to members of the board of directors for their services to the Company based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.
The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The use of the Black-Scholes-Merton option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term.
11
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Due to the lack of Company-specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards.
The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.
The fair value of the Company’s common stock is equal to the closing price on the specified grant date.
Restricted Stock Units (“RSUs”)
The Company recognizes stock-based compensation expense from RSUs ratably over the specified vesting period. The fair value of RSUs is determined to be the closing share price of the Company’s common stock on the grant date.
Common Stock Warrants
The Company accounts for common stock warrants as either equity instruments or liabilities, depending on the specific terms of the warrant agreement. The warrants shall be classified as a liability if (1) the underlying shares are classified as liabilities or (2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee stock-based payments is generally fixed on the grant date and are considered compensatory. For additional discussion on warrants, see Note 10.
Net Loss Per Share
Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.
The table below provides information on shares of the Company’s common stock issuable upon vesting and exercise, as of March 31:
| 2026* | 2025* | |||||||
| Shares issuable upon vesting of RSUs | ||||||||
| Shares issuable upon exercise of stock options | ||||||||
| Shares issuable upon exercise of Lender Warrant (defined below) to purchase common stock | ||||||||
| Shares issuable upon exercise of Underwriter Warrant (defined below) to purchase common stock | ||||||||
| * |
12
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Recently Adopted Accounting Standards
In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies an issuer’s accounting for convertible instruments by reducing the number of accounting models that require separate accounting for embedded conversion features. ASU 2020-06 also simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification and makes targeted improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance. This update will be effective for the Company’s fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Entities can elect to adopt the new guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company adopted this standard as of January 1, 2024. ASU 2020-06 did not have a material impact on the Company’s unaudited condensed financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides amendments to improve reportable segment disclosures requirements. ASU 2023-07 expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company adopted ASU 2023-07 effective January 1, 2024. The adoption of this guidance did not have a material impact on the Company’s related disclosures.
3. PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following at the dates indicated:
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Website | $ | $ | ||||||
| Computer equipment and purchased software | ||||||||
| Equipment | ||||||||
| Furniture and fixtures | ||||||||
| Leasehold improvements | ||||||||
| Total property and equipment | ||||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| Total property and equipment, net | $ | $ | ||||||
Depreciation
expense for property and equipment was $
4. INTERNALLY DEVELOPED SOFTWARE, NET
During
the year ended December 31, 2025, the Company capitalized $
During
the three months ended March 31, 2026, the Company capitalized $
The
Company recognized $
13
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
5. OTHER INTANGIBLE ASSETS, NET
During
the year ended December 31, 2025, the Company did not sequence any FFPE blocks and therefore did not capitalize any sequenced data as
other intangible assets. The Company recognized $
During
the year ended December 31, 2025, the Company write-off the net value of other intangible assets of approximately $
6. FAIR VALUE MEASUREMENTS
As of March 31, 2026 and December 31, 2025, the Company did have any assets or liabilities measured at fair value on a recurring basis.
7. COMMITMENTS AND CONTINGENCIES
Leases
On July 2, 2024, the Company entered into a new operating lease (the “Woburn Lease”) of office space in Woburn, Massachusetts (the “Woburn Premises”) for a term of five years and two months, commencing on September 1, 2024, and terminating on October 30, 2029. The Company has a one-time option to extend the term of the Woburn Lease for one additional term of five years, provided that the Company is not in arrears in any payment of rent, the payment of any outstanding invoice, or otherwise in default. On June 28, 2024, the Company exercised a termination option included in the lease agreement of its former office space in Lexington, Massachusetts, and terminated the lease effective August 31, 2024.
Right-of-use
assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.
ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot
be readily determined, its incremental borrowing rate. The Company used the interest rate of
There are no material residual guarantees associated with any of the Company’s leases, and there are no significant restrictions or covenants included in the Company’s lease agreements. There was sublease rental income for the three months ended March 31, 2026, and the Company is not the lessor in any lease arrangement, and there were no related-party lease agreements.
Lease Costs
The table below presents certain information related to the lease costs for the Company’s operating lease for the three months ended March 31, 2026:
| Operating lease expense | $ | |||
| Short-term lease expense | ||||
| Total lease cost | $ |
14
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Lease Position as of March 31, 2026
Right-of-use lease assets and lease liabilities for the Company’s operating lease as of March 31, 2026 were recorded in the balance sheet as follows:
| Assets | ||||
| Operating lease right-of-use assets | $ | |||
| Total lease assets | $ | |||
| Liabilities | ||||
| Current liabilities: | ||||
| Operating lease liability – current portion | $ | |||
| Non-current liabilities: | ||||
| Operating lease liability – net of current portion | ||||
| Total lease liability | $ | |||
Lease Terms and Discount Rate
The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating lease as of March 31, 2026:
| Weighted average remaining lease term (in years) – operating lease | ||||
| Weighted average discount rate – operating lease | % |
Undiscounted Cash Flows
Future lease payments included in the measurement of lease liabilities on the balance sheet are as follows:
| 2026 (excluding the three months ended March 31, 2026) | $ | |||
| 2027 | ||||
| 2028 | ||||
| Thereafter | ||||
| Total future minimum lease payments | ||||
| Less effect of discounting | ( | ) | ||
| Present value of future minimum lease payments | $ |
Rent
expense for the three months ended March 31, 2026 and 2025 amounted to $
Cash Flows
Supplemental cash flow information related to the operating lease for the three months ended March 31, 2026 was as follows:
| Non-cash operating lease expense (operating cash flow) | $ | |||
| Change in operating lease liabilities (operating cash flow) | $ | ( | ) |
15
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Sales Tax Payable
The majority of the Company’s customers are researchers, universities, hospitals, and not-for-profit entities that were believed by the Company to have a sales and use tax exemption that generally excludes them from paying sales taxes. The main types of specimens the Company sells are blood, blood plasma, human tissue, human parts, and human bodily fluids and only a few of these products are typically not taxable in some states regardless of the buyer’s tax exemption status. The Company historically has not collected sales tax in states where it had sales. Had the Company contemporaneously collected and remitted sales tax for all customers and in all jurisdictions where it would have been required, there would have been no material impact on the Company’s unaudited condensed financial statements.
As a result of an entity-wide risk assessment process that commenced in the second quarter of 2023, the Company engaged external tax consultant advisors to complement internal resources and efforts to provide support in assessing the appropriate sales tax treatment associated with the Company’s products for all prior years in which the Company had generated revenue, to assist with the facilitation and tracking of Voluntary Disclosure Agreements (“VDAs”) in jurisdictions where a potential tax liability may exist and to assist with the implementation of a sales tax software platform solution for the calculation, communication, collection, and remittance of sales tax for all non-exempt future sales.
From the Company’s inception through the filing date of this Quarterly Report, the Company now believes that an obligation to collect and remit sales tax existed for certain of its sales of products to certain of its customers. The Company has analyzed its product sales, on an invoice-by-invoice and customer-by-customer basis, to determine which products are subject to sales tax in each jurisdiction, and determining which of its customers are exempt from sales tax, and which customers who were not exempt from sales tax have already paid compensating use tax to the appropriate jurisdiction. Part of this process includes requesting and obtaining exemption letters or representations from its customers or proof of payment of their compensating use tax. As the Company continues to make progress on this project, certain customers have notified the Company that they are not exempt from the payment of sales tax and have not remitted use tax and the Company has started to invoice such customers for past sales tax due.
In
2023, the Company established and accrued a reliable point estimate with a maximum potential of the sales tax liability of approximately
$
During
the year ended December 31, 2024, the Company received additional sales tax exemption letters or representations from customers. In addition
to this, the Company received confirmation from certain tax jurisdictions in which it had previously accrued a potential tax liability
that its specimens are exempt from tax in those jurisdictions, therefore, the Company reversed the accrued liability associated with
those jurisdictions. The Company also registered in certain states and commenced the filing and remittance of sales taxes. These factors
contributed to the reduction of the sales tax liability to approximately $
During
the year ended December 31, 2025, the Company received additional sales tax certificates from customers. As of December 31, 2025, the
Company has a sales tax liability of approximately $
As
of March 31, 2026, the Company has a sales tax liability of approximately $
As
of March 31, 2026, the Company had recovered approximately $
16
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Legal Proceedings
From time to time the Company is involved in litigation, claims, and other proceedings arising in the ordinary course of business. Such litigation and other proceedings may include, but are not limited to, actions relating to employment law and misclassification, intellectual property, commercial or contractual claims, or other consumer protection statutes. Litigation and other disputes are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur. As of March 31, 2026, there were legal disputes filed against the Company.
Resignation of Chief Information Officer and Filing of Demand for Arbitration
On July 25, 2024, Benjamin Bielak, the Company’s Chief Information Officer until his resignation on July 14, 2024, initiated a Demand for Arbitration against the Company with the American Arbitration Association, pursuant to the dispute resolution provisions contained in Mr. Bielak’s employment agreement. The terms and conditions of Mr. Bielak’s employment with the Company were governed by his employment agreement.
In
his Demand for Arbitration, Mr. Bielak claims that the Company failed to provide him with certain bonus payments allegedly due to him
for work performed in 2023 and 2024. Mr. Bielak also claims that the Company failed to provide him with severance payments allegedly
due pursuant to the provisions of his employment agreement. The total amount of Mr. Bielak’s claim for alleged damages is $
During
the year ended December 31, 2025, the Company settled this legal matter and the parties agreed to a $
EGS- Ellenoff Grossman & Schole LLP (“EGS”)
On or
around November 14, 2024, EGS initiated a claim against the Company for $
On
February 15, 2026, the Company signed a settlement agreement pursuant to the existing legal matter with EGS. Per agreement, the parties
agreed to a $
Settlement Agreement with Focus Technology Solutions, LLC
On
December 9, 2024, Focus Technologies, Inc. (“Focus”) filed a complaint against the Company in the Superior Court of Suffolk
County, Massachusetts, alleging non-payment under agreements dated July 29, 2022, related to the provision of information technology
services. Focus is seeking approximately $
To
restore service, the parties entered into a settlement agreement on February 11, 2025 (the “Settlement Agreement”), under
which the Company agreed to pay $
Focus
has sought to amend its complaint to enforce the Settlement Agreement and has requested pre-judgment security in the amount of $
On
April 10, 2025, the Court partially granted Focus’ Motion for Pre-Judgment Security. The Company is required to open a dedicated
bank account by April 20, 2025 and deposit
17
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
On
September 3, 2025, Focus reduced their global settlement demand to $
The Company will continue to seek relief from the pre-judgment security, and its counterclaim against Focus is still pending.
Azenta US, Inc. (“Azenta”)
On
or around January 15, 2025, Azenta initiated a claim against the Company for $
Krisbio, LLC (“Krisbio”)
On
or about September 23, 2025 the Company was served with a Summons and Complaint in the matter of Krisbio, LLC v. iSpecimen, Inc. 1:25-CV-12409-JCB
in the U.S. District Court for the District of Massachusetts seeking collection of $
8. STOCKHOLDERS’ EQUITY
The
Company’s authorized capital is
Reverse Stock Split
Subsequent
to the three months ended March 31, 2026,
Preferred Stock
On
December 30, 2025, the Company and the Purchasers have entered into the Agreement pursuant to which the Purchasers have agreed to purchase
an aggregate of
Pursuant
to that certain Placement Agency Agreement, dated as of December 30, 2025, by and between the Company and E.F. Hutton & Co. (“EF
Hutton”), the Company paid EF Hutton a cash fee of
During
the three months ended March 31, 2026,
18
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Underwritten Offering
On
July 23, 2025, the Company entered into an underwriting agreement with WestPark (the “Underwriter”), pursuant to which the
Company agreed to issue and sell, in an underwritten public offering, an aggregate of
As
part of its compensation for acting as Underwriter for the offering, the Company paid the Underwriter a cash fee of
Private Placement Offering
On
July 31, 2025, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company
agreed to issue and sell, in a private placement (the “Private Placement”), an aggregate of
Stock Options
There
were
Warrants
Underwriter Warrants
In
connection with the Company’s underwriting agreement with ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”)
and the representative of the Company’s IPO underwriters, the Company entered into a warrant agreement to purchase up to
Lender Warrant
In
connection with the loan agreement entered into with Western Alliance Bank (the “Lender”) on August 13, 2021, the Company
issued a warrant (the “Lender Warrant”) to the Lender to purchase
19
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
PIPE Warrants
On
December 1, 2021, the Company completed a private placement (the “PIPE”) in which the Company issued warrants (the “PIPE
Warrants”) to purchase up to an aggregate of
On
February 13, 2024, the Company entered into certain warrant repurchase and termination agreements with the holders of the PIPE Warrants
to repurchase the PIPE Warrants for a purchase price equal to $
A summary of total warrant activity during the three months ended March 31, 2026 is as follows:
| Weighted | ||||||||||||
| Weighted | Average Remaining | |||||||||||
Warrants Outstanding | Average Exercise Price | Contractual Term in Years | ||||||||||
| Balance at December 31, 2024 | $ | |||||||||||
| Granted | ||||||||||||
| Exercised | ( | ) | — | |||||||||
| Balance at December 31, 2025 | ||||||||||||
| Exercised | ( | ) | ||||||||||
| Balance at March 31, 2026 | $ | |||||||||||
9. STOCK-BASED COMPENSATION
Stock Incentive Plans
2021 Plan
In March 2021, the Company adopted the iSpecimen Inc. 2021 Stock Incentive Plan, which was subsequently amended in June 2021 and then on May 25, 2022 (the “2021 Plan”). The 2021 Plan was adopted to enhance the Company’s ability to attract, retain and motivate employees, officers, directors, consultants, and advisors by providing such persons with equity ownership opportunities and performance-based incentives. The 2021 Plan authorizes options, restricted stock, RSUs and other stock-based awards. The Company’s board of directors, or any committee to which the board of directors delegates such authority, has the sole discretion in administering, interpreting, amending, or accelerating the 2021 Plan. Awards may be made under the 2021 Plan for up to 760 shares of the Company’s common stock, and the 2021 Plan was made effective with the completion of the IPO.
On
May 24, 2023, at the Company’s annual meeting of stockholders, the stockholders approved an amendment to the 2021 Plan to increase
the number of shares under the 2021 Plan from
No equity
awards were granted under the 2021 Plan during the three months ended March 31, 2026 and 2025. As of March 31, 2026, there were
20
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
2013 Plan
The
iSpecimen Inc. 2013 Stock Incentive Plan (the “2013 Plan”) was adopted on April 12, 2013 and subsequently amended on July
29, 2015. The aggregate number of shares of common stock that may be issued pursuant to the 2013 Plan was
No equity
awards were granted under the 2013 Plan during the three months ended March 31, 2026 and 2025. According to the 2013 Plan, which was
adopted by the Company’s board of directors on April 12, 2013, awards shall be granted under the 2013 Plan after the completion
of
Stock Options
A summary of stock option activity under the 2021 Plan and 2013 Plan is as follows:
| Weighted | ||||||||||||||||
| Average | ||||||||||||||||
Options Outstanding | Weighted Average Exercise Price | Remaining Contractual Term in Years | Aggregate Intrinsic Value | |||||||||||||
| Balance at December 31, 2024 | $ | $ | ||||||||||||||
| Granted | — | |||||||||||||||
| Exercised | — | |||||||||||||||
| Cancelled/forfeited | ( | ) | — | |||||||||||||
| Balance at December 31, 2025 and March 31, 2026 | $ | $ | ||||||||||||||
| Options exercisable at March 31, 2026 | $ | $ | ||||||||||||||
The aggregate intrinsic value in the table above represents the difference between the Company’s stock price as of the balance sheet date and the exercise price of each in-the-money option on the last day of the period. No stock options were exercised during the three months ended March 31, 2026 and 2025.
No
stock options granted during the three months ended March 31, 2025. The weighted average grant date fair value of stock options issued
in the three months ended March 31, 2025 was $
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Technology | $ | $ | ||||||
| Sales and marketing | ||||||||
| Supply development | ||||||||
| Fulfillment | ||||||||
| General and administrative | ||||||||
| Total stock options expense | $ | $ | ||||||
As
of March 31, 2026 and 2025, a total of $
21
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Restricted Stock Units
A summary of RSUs activity under the 2021 Plan and 2013 Plan is as follows:
| Weighted | ||||||||
RSUs Outstanding | Average Grant Date Fair Value | |||||||
| Unvested Balance at December 31, 2024 | $ | |||||||
| Granted | ||||||||
| Vested | ( | ) | ||||||
| Forfeited | ( | ) | ||||||
| Unvested Balance at December 31, 2025 | $ | |||||||
| Granted | ||||||||
| Vested | ( | ) | ||||||
| Forfeited | ||||||||
| Unvested Balance at March 31, 2026 | $ | |||||||
The Company recorded RSUs compensation expense during the three months ended March 31, 2026 and 2025 as follows:
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Technology | $ | $ | ||||||
| Sales and marketing | ||||||||
| Supply development | ||||||||
| Fulfillment | ||||||||
| General and administrative (recovery) | ( | ) | ||||||
| Total stock options expense | $ | $ | ||||||
As of March 31, 2026 and 2025, the total unrecognized
stock-based compensation expense related to unvested RSUs was $
10. INCOME TAXES
As
of March 31, 2026 and December 31, 2025, the Company had federal net operating loss carryforwards of approximately $
Due to changes in ownership provisions of the Internal Revenue Code, the availability of the Company’s NOL carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code against taxable income in the future period, which could substantially limit the eventual utilization of such carryforwards.
11. SEGMENT AND GEOGRAPHIC INFORMATION
The
Company has
22
iSpecimen Inc.
Notes to Unaudited Condensed Financial Statements
Set out below is information about the assets and liabilities as at March 31, 2026 and December 31, 2025 and profit or loss from each segment for the three months ended March 31, 2026 and 2025.
March 31, 2026 | December 31, 2025 | |||||||
| Financial statement line item: | ||||||||
| Reportable segment assets | $ | $ | ||||||
| Reportable segment liabilities | ||||||||
Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Financial statement line item: | ||||||||
| Revenues from external customers | $ | $ | ||||||
| Less: | ||||||||
| Cost of revenue, excluding amortization | ||||||||
| Technology expenses, excluding amortization | ||||||||
| Sales and marketing expenses | ||||||||
| Supply development expenses | ||||||||
| Fulfillment expenses | ||||||||
| Other segment items (a) | ||||||||
| Depreciation & amortization expense | ||||||||
| Interest expense | ||||||||
| Interest income | ( | ) | ( | ) | ||||
| Interest and penalties on sales tax liability | ||||||||
| Income tax expense | ||||||||
| Reportable segment income (loss) | $ | ( | ) | $ | ( | ) | ||
| (a) |
The Company’s reportable business segment sell their goods in four geographic locations:
| ● | Americas | |
| ● | Europe | |
| ● | Middle East/Africa | |
| ● | Asia Pacific |
The following table represents the percentage of total revenue by geographic area, based on the location of the customer for the three months ended March 31, 2026 and 2025, respectively.
| 2026 | 2025 | |||||||
| Americas | % | % | ||||||
| Europe, Middle East and Africa | % | % | ||||||
| Asia Pacific | % | |||||||
12. SUBSEQUENT EVENTS
On April 9, 2026, the Company’s board of directors approved a one-for-forty (1:40) reverse stock split of the Company’s issued and outstanding shares of common stock. The Reverse Stock Split became effective on April 27, 2026, and the Company’s common stock began trading on a split-adjusted basis on Nasdaq on April 28, 2026.
On
May 8, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited
investors (the “Investors”), pursuant to which the Company agreed to issue and sell
23
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to iSpecimen Inc. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance, or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2026. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We were incorporated in 2009 under the laws of the state of Delaware. Our mission is to accelerate life science research and development via a single global marketplace platform, the iSpecimen Marketplace, which connects researchers to subjects, specimens, and associated data. We are headquartered in Woburn, Massachusetts. We operate as one operating and reporting segment.
In addition to creating a single global platform where both specimen providers and researchers can connect, the platform automates the process of searching for and selecting specimens for research. The platform taps into healthcare provider data to gain insights into the available samples in biobanks or laboratories, or to gain insights into the patient populations to support specimen collections directly from research subjects. The platform receives de-identified data from electronic medical records, laboratory information systems, and other healthcare data sources of available specimens and research subjects and harmonizes the data across all participating organizations.
Researchers can search this data using our intuitive, web-based user interface to obtain specimens more efficiently. They can instantly find the specific specimens they need for their studies, request quotes for these specimens or for custom collections directly from research subjects, place orders, and track and manage their specimens and associated data across projects.
Biospecimen providers also gain efficiencies using the iSpecimen Marketplace, not only because the platform provides instant access to a large researcher base, but because the technology orchestrates the bioprocurement workflow from specimen request to fulfillment. Specimen providers can access intuitive dashboards to view requests, create proposals, and track and manage their orders.
Finally, the platform helps with administrative and reporting functions for researchers, suppliers, and our internal personnel, including user and compliance management.
The iSpecimen Marketplace is composed of four major functional areas: search, workflow, data, and administration and reporting. As capital is made available to do so, we continue to invest in the evolution of these areas to improve engagement with the platform and liquidity across it. Our core business objective is to retain and grow both researcher and supplier usage of our platform to support biospecimen procurement, as well as to position our Company to explore other adjacent business opportunities that can benefit from the use of the iSpecimen Marketplace.
24
The iSpecimen Marketplace currently supports the supply chain management and bioprocurement process for specimens and associated data. We generate revenue by procuring various specimens from hospitals, laboratories, and other supply sites comprising our network, and delivering them to our medical research customers using our proprietary software to identify and locate the required specimens. Costs paid to acquire specimens from hospitals and laboratories generally vary depending upon the sample type, collection requirements, and data provided. We generally operate in a “just in time” fashion, meaning we procure specimens from our suppliers and distribute specimens to our customers after we obtain an order for specimens from a research client. Generally, we do not speculatively purchase and bank samples in anticipation of future, unspecified needs. We believe our approach offers many advantages over a more traditional inventory-based supplier business model where biorepositories take inventory risks, and where inventory turnover and cash conversion cycles can be lengthy.
Private Placement Offering
On July 31, 2025, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), an aggregate of 38,996 securities, comprised of (i) 6,684 shares of Common Stock at a purchase price of $44.88 per Share, and (ii) pre-funded warrants to purchase up to 32,311 shares of Common Stock at a purchase price of $44.88 per Share, for aggregate gross proceeds of $1,749,998, before deducting placement agent fees and other offering expenses. The pre-funded warrants are immediately exercisable until such time as the pre-funded warrants are exercised in full. The Private Placement closed on August 4, 2025.
On May 8, 2026, the Company entered into the Purchase Agreement with certain Investors, pursuant to which the Company agreed to issue and sell 488,281 Shares, at a purchase price of $5.12 per Share. In lieu of Shares that would otherwise result in a purchaser’s beneficial ownership exceeding 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such Shares, certain purchasers may elect to receive Pre-Funded Warrants at a purchase price of $5.1199 per Pre-Funded Warrant (equal to the per Share purchase price less $0.0001). Each Pre-Funded Warrant is exercisable immediately upon issuance for one share of Common Stock at an exercise price of $0.0001 per share and will remain exercisable until exercised in full. The offering closed on May 11, 2026.
Reverse Stock Split
On October 9, 2023, we received a notification from Nasdaq that our Common Stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market.
On July 19, 2024, our stockholders approved a proposal to amend our Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding shares of common stock, as well as any shares of common stock held by the Company in treasury, at a ratio in the range from 1-for-10 to 1-for-20.
On August 19, 2024, the Board approved a one-for-twenty (1:20) reverse stock split of our issued and outstanding shares of common stock. On September 13, 2024, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment to our Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split became effective on September 13, 2024, and our common stock began trading on a split-adjusted basis on Nasdaq on September 16, 2024.
On October 1, 2024, we received a notification from Nasdaq that the Staff has determined that for the last 11 consecutive business days, from September 16, 2024 to September 30, 2024, the closing bid price of our Common Stock was $1.00 per share or greater. Accordingly, we regained compliance with Listing Rule 5559(a)(2).
Except as otherwise indicated, all references to our common stock, share data, per share data and related information have been adjusted for the Reverse Stock Split ratio of 1-for-20 as if they had occurred at the beginning of the earliest period presented. The Reverse Stock Split combined each 20 shares of our outstanding common stock and treasury shares into one share of common stock without any change in the par value per share, and the Reverse Stock Split correspondingly adjusted, among other things, the exercise rate of our warrants and options into our common stock. No fractional shares were issued in connection with the Reverse Stock Split, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.
On April 9, 2026, the Company’s board of directors approved a one-for-forty (1:40) reverse stock split of the Company’s issued and outstanding shares of common stock. The Reverse Stock Split became effective on April 27, 2026, and the Company’s common stock began trading on a split-adjusted basis on Nasdaq on April 28, 2026.
25
Underwritten Offering
On July 23, 2025, the Company entered into an underwriting agreement with WestPark (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten public offering, an aggregate of 142,857 securities, consisting of (i) 37,066 shares of Common Stock, and (ii) pre-funded warrants to purchase up to 105,791 shares of Common Stock, at an exercise price of $0.004 per share. The securities were sold at a public offering price of $28 per share (or $27.99 per pre-funded warrant), for gross proceeds of $3,999,574, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The pre-funded warrants are immediately exercisable until such time as the pre-funded warrants are exercised in full. The offering closed on July 25, 2025.
As part of its compensation for acting as Underwriter for the offering, the Company paid the Underwriter a cash fee of 4.0% of the aggregate gross proceeds plus reimbursement of certain expenses and legal fees. The Company incurred offering costs of approximately $419,983 and settled non-offering related legal fees of approximately $93,837, resulting in net proceeds of approximately $3,485,754.
Impact of the Current Economy
The Company’s financial performance is subject to global economic conditions and their impact on levels of spending by our customer research organizations, particularly discretionary spending for procurement of specimens used for research. Economic recessions may have adverse consequences across industries, including the health and biospecimen industries, which may adversely affect our business and financial condition. We increased our allowance for doubtful accounts in accounts receivables by $369 as of March 31, 2026 due to certain customers either lack liquidity or have filed for bankruptcy. We have enhanced procedures related to our credit check process for new and existing customers in the first quarter of 2026 to mitigate the risk to future collectability of receivables.
Changes in general market, economic and political conditions in domestic and foreign economies or financial markets, including fluctuation in stock markets resulting from, among other things, trends in the economy and inflation, as are being currently experienced, may result in a reduction in researchers’ demand for specimens due to the research organization’s inability to obtain funding.
To further address the current market conditions, we have taken steps, which include but are not limited to, reevaluating our pricing in order to be more competitive, creating campaigns to highlight and fast-track high demand items, enhancing internal team communications to accelerate the sales cycle, moving to a new line of business structure organized by our internal categorization of biospecimen suppliers capabilities to increase efficiency in operations, implementation of next day quotes to increase conversion ratios of quotes to purchase orders, and initiation of efforts to decrease expenditures through reductions in our workforce.
We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects.
Impact of the Russian-Ukrainian War on Our Operations
Our business was negatively impacted during the first half of 2022 by the ongoing war between Russia and Ukraine. At the start of the war, we had approximately $1 million of purchase orders that were slated to be fulfilled by our supply network in Ukraine and Russia. This supply network was shut down at the start of the war. Ukrainian suppliers were disabled due to war conditions and evacuations and some of our Russian suppliers were disabled by sanctions. While we mobilized to shift these purchase orders to other suppliers in the network, the process of specimen collections from other supply sites took time, which caused a delay in the fulfillment of such purchase orders. Alternate suppliers do not have the same favorable unit economics or specimen collection rates, and this also impacted our margins. Additionally, key resources were diverted from operations to resolving the re-fulfillment issues caused by the conflict.
26
As of March 31, 2026, our supply sites in Russia that had not been under sanctions were accessible and our supply sites in Ukraine were mostly reopened. However, logistics and transportation of specimens out of the country of Ukraine remains challenging and not as economically feasible as they were prior to the beginning of the war. Due to the uncertainty caused by the ongoing war, Ukrainian and Russian suppliers may again become inaccessible to us. Therefore, as long as the uncertainty continues, our policy is to ensure at a purchase order level that an order is not solely sourced from the two countries. The short and long-term implications of the war are difficult to predict as of the date of this Form 10-Q. The imposition of more sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business and the businesses of our supply partners, especially those in Ukraine and Russia. Because of the highly uncertain and dynamic nature of these events, it is not currently possible to estimate the impact of the war on our business and the companies from which we obtain supplies and distribute specimens.
Known Trends, Demands, Commitments, Events or Uncertainties Impacting Our Business
Chief Executive Officer Initiatives
The Company’s mission remains to accelerate life sciences research and development, pursuant to a single global marketplace platform. Executive management of the Company continues to review the Company’s structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business.
During the three months ended March 31, 2026, the Company continued its efforts, which had begun in 2023, to decrease its capital and operational expenditures by cutting costs and right sizing the Company through a reduction in workforce while streamlining operations and rationalizing resources to focus on key market opportunities. The reductions in workforce since January 1, 2024 through December 31, 2025, cumulatively resulted in an estimated reduction in monthly compensation costs of approximately 67% and technology costs of approximately 39% during the year December 31, 2025 when compared to the year ended December 31, 2024. During the first quarter of 2026, the reductions in workforce resulted in an estimated reduction in monthly compensation costs of approximately 70% and technology costs of approximately 36% during the three months ended March 31, 2026, when compared to the three months ended March 31, 2025.
During the year ended December 31, 2023, we performed operational process improvement activities to increase collaboration within and between departments. We moved to a line of business structure organized by our internal categorization of biospecimen suppliers’ capabilities, which has increased efficiency in our operations and throughout the Company. We continue to see benefits from this move.
We completed the implementation of a next day quote system in the third quarter of 2023 and we continue to see positive results in 2024 and up to the first quarter of 2026, as evidenced by increased conversion ratios of quotes to purchase orders of 44%. Previously, it took an extended number of days to complete a feasibility study in order to provide a customer quote, which negatively impacted the time to convert a quote to a purchase order.
While we are committed to developing our technology, we are investing at a significantly lower level in 2025 when compared to 2024 and prior years, while we focus on growing our revenues through key market opportunities and assessing our capital raise prospects. During the three months ended March 31, 2026 and 2025, we capitalized approximately $1,700,000 and $0, respectively, of internally developed software costs, of which $1,000,000 was reclassified from software under development. These investments have resulted in multiple process improvements, streamlining workflows and providing deeper insights into orders for all users of our marketplace.
We have shifted our focus from high volume to high value suppliers that meet our newly defined costs, quality and speed requirements. We established business criteria that focus on supplier capabilities and revenue growth strategies as well as technology criteria for integrating onto our iSpecimen Marketplace platform and participating with us. In the year ended December 31, 2024, we terminated 180 supplier agreements and are in the final stages of what we call our “supplier network refresh project”. This has resulted in fewer key suppliers, supported by our lean workforce and processes more effectively. We have been reengaging our suppliers in more meaningful manner which assisted us in the implementation of our next day quote system. We now have a key supplier program whereby we proactively engage with the suppliers to promote our business through marketing campaigns and supplier organizations’ offerings.
27
Going forward, we will leverage the hard work detailed above to support a sales overhaul. As we wrap up several operationally focused projects, we will now be re-organizing the commercial end of the business. This starts with a new account-based sales approach and the introduction of an outbound sales team to ensure we are meeting our customers and prospects where they are. We are also bringing marketing and sales closer to enable the same efficiencies within the commercial organization, the same way that our line of business realignment brought to the operational side of the business this past year. This refined approach and tighter internal integration will continue to accelerate our next day quote program and deepen customer relationships for increased predictability.
Our strategic business intelligence initiatives have enabled us to understand our market and business better than ever before. We now have the capabilities to use data to know how and where to grow. We will continue adjusting the shape of the business toward our core competencies and the market. We can better use key insights from our sales data to understand market needs to assess areas where we lose deals today, through multiple lenses, in order to adjust our supplier network and marketing efforts accordingly. Conversely, this strategy will also allow us to assess areas where we win with an eye toward expanding deeper into those market niches or disease states.
Following the completion of our supplier network refresh efforts, we will have a better than ever understanding of our key supplier capabilities, specifically focused on their pricing, quality, and speed. Using this information and the outputs of our strategic business intelligence capabilities, we will continue to be able to increase the speed of an opportunity through our sales funnel and our conversion ratios, which we believe will continue to grow our revenue.
Components of Our Results of Operations
Revenue
We generate revenue by procuring various specimens from hospitals, laboratories, and other supply sites, for our medical research customers using our proprietary software, the iSpecimen Marketplace, to identify, locate, and ultimately validate the required specimens to our customers’ requested specifications. The Company’s performance obligation is to procure a specimen meeting the customer specification(s) from a supplier, on a “best efforts” basis, for our customer at the agreed price per specimen as indicated in the customer contract with the Company. We do not currently charge suppliers or customers for the use of our proprietary software. Each customer will execute a material and data use agreement with the Company or agree to online purchase terms, each of which includes terms such as specimen and data use, shipment terms, payment and cancellation terms. These are then supplemented by purchase orders that specify specimen requirements including detailed inclusion/exclusion criteria, quantities to be collected, and pricing. Collectively, these customer agreements represent the Company’s contracts with its customer. Generally, contracts have fixed unit pricing. For certain specimen orders, a refundable customer deposit may be required prior to order fulfillment depending on project set-up requirements, presented as deferred revenue. The Company expects to recognize the deferred revenue within the next twelve months.
We recognize revenue over time, as we have created an asset with no alternative use and we have an enforceable right to payment for performance completed to date. At contract inception, we review a contract and related order upon receipt to determine if the specimen ordered has an alternative use to us. Generally, specimens ordered do not have an alternative future use to us and our performance obligation is satisfied when the related specimens are accessioned. We use an output method to recognize revenue for specimens with no alternative future use. The output is measured based on the number of specimens accessioned.
Customers are typically invoiced upon shipment. Depending on the quantity of specimens ordered, it may take several accounting periods to completely fulfill a purchase order. In other words, there can be multiple invoices issued for a single purchase order, reflecting the specimens being accessioned over time. However, specimens are generally shipped as soon as possible after they have been accessioned.
During 2024, the Company recognized its revenue when the related specimens are delivered.
28
Cost of Revenue
Cost of revenue primarily consists of the purchase price to acquire specimens from hospitals and laboratories, inbound and outbound shipping costs, supply costs related to samples, payment processing and related transaction costs, costs paid to the supply sites to support sample collections, amortization of capitalized sequenced data costs and other assets related to sequenced data. Shipping costs upon receipt of products from suppliers are recognized in cost of revenue.
Technology
Technology costs include consulting fees, payroll and related expenses for employees involved in the development and implementation of our technology; software license and system maintenance fees, outsourced data center costs, data management costs, amortization of internally developed software, and other expenses necessary to support technology initiatives. Collectively, these costs reflect the efforts we make to offer a wide variety of products and services to our customers. Technology and data costs are generally expensed as incurred.
A portion of technology costs are related to research and development. Costs incurred for research and development are expensed as incurred, except for software development costs that are eligible for capitalization. Research and development costs primarily include salaries and related expenses, in addition to the cost of external service providers.
Sales and Marketing
Sales and marketing costs primarily consist of payroll and related expenses for personnel engaged in marketing and selling activities, including salaries and sales commissions, travel expenses, public relations and social media costs, ispecimen.com website development and maintenance costs, search engine optimization fees, advertising costs; direct marketing costs, trade shows and events fees, marketing and customer relationship management software, and other marketing-related costs.
Supply Development
We have agreements with supply partners that allow us to procure specimens from them and distribute these samples to customers. Supply development costs primarily include payroll and related expenses for personnel engaged in the development and management of this supply network, related travel expenses, regulatory compliance costs to support the network, and other supply development and management costs.
Fulfillment
Fulfillment costs primarily consist of those costs incurred in operating and staffing operations and customer service teams, including costs attributable to assess the feasibility of specimen requests, creating and managing orders, picking, packaging, and preparing customer orders for shipment, responding to inquiries from customers, and laboratory equipment and supplies.
General and Administrative
General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses for human resources, legal, finance, and executive teams, associated software licenses, facilities, and equipment expenses, such as depreciation and amortization expense and rent, outside legal expenses, insurance costs, and other general and administrative costs.
29
Financial Operations Overview and Analysis for the Three Months Ended March 31, 2026 and 2025 (Unaudited)
Comparison of the Three Months Ended March 31, 2026 and 2025
Three Months Ended March 31, | Change | |||||||||||||||
| 2026 | 2025 | Dollars | Percentage | |||||||||||||
| Revenue | $ | 156,009 | $ | 1,057,510 | $ | (901,501 | ) | (85 | )% | |||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue | 84,410 | 657,279 | (572,869 | ) | (87 | )% | ||||||||||
| Technology | 247,549 | 545,367 | (297,818 | ) | (55 | )% | ||||||||||
| Sales and marketing | 1,542,297 | 347,140 | 1,195,157 | 344 | % | |||||||||||
| Supply development | 34,017 | 93,681 | (59,664 | ) | (64 | )% | ||||||||||
| Fulfillment | 105,724 | 293,766 | (188,042 | ) | (64 | )% | ||||||||||
| General and administrative | 680,415 | 758,666 | (78,251 | ) | (10 | )% | ||||||||||
| Total operating expenses | 2,694,412 | 2,695,899 | (1,487 | ) | (0 | )% | ||||||||||
| Loss from operations | (2,538,403 | ) | (1,638,389 | ) | 900,014 | 55 | % | |||||||||
| Other income, net | ||||||||||||||||
| Interest expense | — | (1,946 | ) | 1,946 | 100 | % | ||||||||||
| Interest income | 291 | 2,788 | (2,497 | ) | (90 | )% | ||||||||||
| Interest and penalties on sales tax liability | (1,253 | ) | (18,540 | ) | 17,287 | 100 | % | |||||||||
| Other income (expense), net | 264,144 | (2,309 | ) | 266,453 | (11,540 | )% | ||||||||||
| Total other income, net | 263,182 | (20,007 | ) | 283,189 | (1,415 | )% | ||||||||||
| Net loss | $ | (2,275,221 | ) | $ | (1,584,482 | ) | 616,825 | 37 | % | |||||||
Revenue
Revenue decreased by approximately $902,000, or 85%, from approximately $1,058,000 for the three months ended March 31, 2025 to approximately $156,000 for the three months ended March 31, 2026. This was primarily due to the decrease of 1,419, or approximately 61%, in specimen count from 2,309 specimens in the three months ended March 31, 2025 to 890 specimens in the three months ended March 31, 2026.
The effect of the decrease in specimen count also caused the average selling price per specimen to decrease by $283, or 62%, from approximately $458 during the three months ended March 31, 2025 to $175 during the three months ended March 31, 2026. The significant decline in revenue was mainly due to decrease in customers’ orders and procurement during the three months ended March 31, 2026.
Cost of Revenue
Cost of revenue decreased by approximately $573,000, or 87%, from approximately $657,000 for the three months ended March 31, 2025 to approximately $84,000 for the three months ended March 31, 2026, which was attributable to an approximately 62% decrease in the number of specimens delivered for the current period as compared to the accessioned specimens in the same period in the prior year, and an approximately $190, or 67%, decrease in the average cost per specimen.
Technology
Technology expenses decreased by approximately $298,000, or 55%, from approximately $545,000 for the three months ended March 31, 2025 to approximately $248,000 for the three months ended March 31, 2026. The decrease was related to decrease in amortization expense of internally developed software of approximately $234,000 and payroll and related expenses of approximately $81,000, which was partially offset by the increase in professional fees of approximately $17,000.
30
Technology expenditures capitalized as internally developed software costs increased by approximately $700,000, or 100%, from approximately $0 for the three months ended March 31, 2025 to $700,000 for the three months ended March 31, 2026 due to installation of a new platform to modernize the Company’s internally developed software, as part of the digital transformation program in 2025 when compared to the reductions in workforce stemming from our decision to invest in the software at a significantly lower level in 2025 and 2024.
Sales and Marketing Expenses
Sales and marketing expenses increased by approximately $1,195,000, or 344%, from approximately $347,000 for the three months ended March 31, 2025 to approximately $1,542,000 for the three months ended March 31, 2026. The increase was primarily attributable to increases in external marketing expense of approximately $1,501,000, which was partially offset by the decrease in payroll and related expenses of approximately $259,000 and advertising and promotions expense of approximately $45,000.
Supply Development
Supply development expenses decreased by approximately $60,000, or 64%, from approximately $94,000 for the three months ended March 31, 2025 to approximately $34,000 for the three months ended March 31, 2026. The decrease was primarily attributable to a decrease in payroll and related expenses of approximately $60,000.
Fulfillment
Fulfillment costs decreased by approximately $188,000, or 64%, from approximately $294,000 for the three months ended March 31, 2025 to approximately $106,000 for the three months ended March 31, 2026. The decrease was primarily attributable to a decrease in payroll and related expenses of approximately $185,000 for personnel engaged in order fulfillment and general operating expenses related to fulfillment of approximately $3,000.
General and Administrative Expenses
General and administrative expenses decreased by approximately $78,000, or 10%, from approximately $759,000 for the three months ended March 31, 2025 to approximately $680,000 for the three months ended March 31, 2026. The decrease was attributable to a decrease in professional fees of approximately $91,000, utilities and facilities expenses of approximately $2,000, doubtful account expense of approximately $111,000, amortization and depreciation of approximately $15,000, taxes and insurance of approximately $95,000, and franchise tax of $20,000, which were partially offset by the increase in compensation costs of approximately $253,000 and general operating expenses of approximately $3,000.
Other Income, net
Other income, net, increased by approximately $283,000, or 1,415%, from an income of approximately $20,000 for the three months ended March 31, 2025 to approximately $263,000 for the three months ended March 31, 2026. The decrease in other income, net, was attributable to the increase of other income of approximately $266,000, decrease in interest income of approximately $2,000, decrease in recovery of interest and penalties on sales tax liability of approximately $17,000 and increase in interest expense of approximately $2,000.
31
Liquidity and Capital Resources
| March 31, | December 31, | Change | ||||||||||||||
| 2026 | 2025 | Dollars | Percentage | |||||||||||||
| (unaudited) | ||||||||||||||||
| Balance Sheet Data: | ||||||||||||||||
| Cash and cash equivalents | $ | 2,818,989 | $ | 6,880,835 | $ | (4,061,846 | ) | (59 | )% | |||||||
| Working capital | 2,115,634 | 723,284 | 1,392,350 | 193 | % | |||||||||||
| Total assets | 6,609,658 | 9,531,410 | (2,921,752 | ) | (31 | )% | ||||||||||
| Total stockholders’ equity | 794,038 | 3,088,231 | (2,294,193 | ) | (74 | )% | ||||||||||
Three Months Ended March 31, | Change | |||||||||||||||
| 2026 | 2025 | Dollars | Percentage | |||||||||||||
| (unaudited) | ||||||||||||||||
| Statement of Cash Flow Data: | ||||||||||||||||
| Net cash flows used in operating activities | $ | (3,361,846 | ) | $ | (1,095,845 | ) | $ | (2,266,001 | ) | 207 | % | |||||
| Net cash flows used in investing activities | (700,000 | ) | — | (700,000 | ) | 100 | % | |||||||||
| Net cash flows provided by financing activities | — | — | — | — | % | |||||||||||
| Net increase (decrease) in cash and cash equivalents | $ | (4,061,846 | ) | $ | (1,095,845 | ) | $ | (2,966,001 | ) | |||||||
Capital Resources
We have recurring losses since inception. As of March 31, 2026, our available cash and cash equivalents totaled approximately $2,818,989, which represented a decrease of approximately $4,062,000 from approximately $6,881,000, as of December 31, 2025. We had working capital deficit of approximately $2,116,000, an accumulated deficit of approximately $84,625,000, cash and cash equivalents of approximately $2,819,000 and accounts payable and accrued expenses of approximately $5,351,000. Our continued viability is dependent on the ability to successfully obtain additional working capital and/or ultimately attain profitable operations. During the three months ended March 31, 2026, the Company continued its efforts, which had begun in 2023, to decrease its capital and operational expenditures by cutting costs and right sizing the Company through a reduction in workforce while streamlining operations and rationalizing resources to focus on key market opportunities. The reductions in workforce since January 1, 2024 through December 31, 2025, cumulatively resulted in an estimated reduction in monthly compensation costs of approximately 67% and technology costs of approximately 39% during the year December 31, 2025 when compared to the year ended December 31, 2024. During the first quarter of 2026, the reductions in workforce resulted in an estimated reduction in monthly compensation costs of approximately 70% and technology costs of approximately 36% during the three months ended March 31, 2026, when compared to the three months ended March 31, 2025. While the Company plans to improve its sales and revenues, the Company is taking steps to significantly reduce and manage expenditures to improve its financial position and ensure continued funding of operations. However, as certain elements of the Company’s operating plan are not within the Company’s control, the Company is unable to assess their probability of success. During the year ended December 31, 2025, the Company engaged in raising capital through equity financing as discussed in Note 10.
We may be unsuccessful in increasing our revenues or contain our operating expenses, or we may be unable to raise additional capital on commercially favorable terms. Our failure to generate additional revenues or contain operating costs would have a negative impact on our business, results of operations and financial condition and our ability to continue as a going concern. If we do not generate enough revenue to provide an adequate level of working capital, our business plan will be scaled down further.
These conditions raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date of this Quarterly Report. Management’s plan to mitigate the conditions that raise substantial doubt includes generating additional revenues through its revenue enhancement projects, deferring certain projects and capital expenditures and eliminating certain future operating expenses for us to continue as a going concern. However, there can be no assurance that we will be successful in completing any of these options. As a result, management’s plans cannot be considered probable and thus do not alleviate substantial doubt about our ability to continue as a going concern.
32
Cash Flows
Operating Activities
For the three months ended March 31, 2026, net cash used in operating activities was approximately $3,362,000, which consisted of a net loss of approximately $2,295,000 offset by non-cash charges of approximately $124,000, which included approximately of $134,000 related to amortization of internally developed software, approximately $1,000 in stock-based compensation, approximately $400 in bad debt expense, approximately $2,000 related to depreciation of property and equipment, and approximately $0 related to amortization of other intangible assets.
Total changes in assets and liabilities of approximately $942,000 were attributable to an approximately $85,000 increase in accounts receivable, an approximately $15,000 decrease in operating lease right-of-use asset and an approximately $374,000 decrease in accounts payable, offset by an approximately $507,000 increase in prepaid expenses, an approximately $24,000 decrease in accrued expenses, an approximately $14,000 decrease in operating lease liability and an approximately $3,000 decrease in deferred revenue.
For the three months ended March 31, 2025, net cash used in operating activities was approximately $1,096,000, which consisted of a net loss of approximately $1,584,000 offset by non-cash charges of approximately $486,000, which included approximately of $368,000 related to amortization of internally developed software, approximately $16,000 in stock-based compensation, approximately $37,000 in bad debt expense, approximately $17,000 related to depreciation of property and equipment, and approximately $48,000 related to amortization of other intangible assets.
Total changes in assets and liabilities of approximately $3,000 were attributable to an approximately $752,000 decrease in accounts receivable, an approximately $101,000 decrease in prepaid expenses, an approximately $14,000 decrease in operating lease right-of-use asset, and an approximately $90,000 decrease in deferred revenue, offset by an approximately $411,000 decrease in accounts payable, an approximately $351,000 decrease in accrued expenses and an approximately $12,000 decrease in operating lease liability.
Investing Activities
Net cash used in investing activities was approximately $700,000 for the three months ended March 31, 2026, which consisted of approximately $700,000 of capitalization of intangible assets under development. We intend to continue to use our existing cash to grow our supply network, increase our marketing and sales presence, scale our operations, and for working capital and general corporate purposes.
During the year ended December 31, 2024, we invested approximately $653,000 in further developing our iSpecimen Marketplace technology, in comparison to the cash invested during the year ended December 31, 2023 of approximately $3,767,000.
There was no cash provided by investing activities during the three months ended March 31, 2026.
Financing Activities
There was no cash provided by financing activities during the three months ended March 31, 2026.
There was no cash provided by financing activities during the three months ended March 31, 2025.
33
Effects of Inflation and Supply Chain Shortages
Our operations are heavily reliant on specimen availability, and as a result, we often receive more requests than we can fulfill. While the Company is subject to these types of supply chain constraints that are specific to the specimen industry, we have not been materially affected by the more common supply chain issues currently affecting the economy, specifically surrounding transportation.
We have experienced negative effects of inflation in certain areas of our business due to the high rates of inflation in the world’s current economy. This inflation is affecting employee salaries, which account for a significant portion of our operating costs. Additionally, the costs of supplies have been affected by inflation; however, these costs are not significant to the Company’s results.
Inflation has not had a significant impact on the cost of specimens due to our long-term contracts maintained with vendors, which include revenue sharing plans.
Critical Accounting Policies and Estimates
We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial condition in conformity with GAAP. We apply these accounting policies in a consistent manner. Our significant accounting policies are discussed in Note 2, “Summary of Significant Accounting Policies,” in our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.
The application of critical accounting policies requires that we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. These estimates and assumptions are based on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. We evaluate these estimates and assumptions on an ongoing basis. If actual results ultimately differ from previous estimates, the revisions are included in results of operations in the period in which the actual amounts become known. The critical accounting policies that involve the most significant management judgments and estimates used in preparation of our unaudited condensed financial statements or are the most sensitive to change from outside factors, are discussed in “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes in our critical accounting policies and procedures during the three months ended March 31, 2026.
JOBS Act Transition Period
On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company.
We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) December 31, 2026; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.
34
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not required for smaller reporting companies.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended March 31, 2026, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. These controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, in a manner to allow timely decisions regarding required disclosures. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of March 31, 2026 due to the following material weakness in internal control over financial reporting:
| ● | The Company did not design and maintain adequate controls to maintain appropriate documentation for the tax-exempt status of its customers, calculate and collect sales tax at point of sale, and subsequently report and remit in a timely manner to the relevant tax jurisdictions sales tax obligations. |
Notwithstanding the existence of the material weakness described above, management believes that the unaudited condensed financial statements included in this Quarterly Report fairly present, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented, in conformity with GAAP.
Management’s Plan for Remediation
The material weakness described above was identified as a result of an entity-wide risk assessment process that commenced in the quarter ended June 30, 2023. The Company is in the process of implementing a remediation plan to improve our internal control over financial reporting and to remediate the related control deficiencies that led to the material weakness. In response to these deficiencies, management, with the oversight of the Audit Committee of the Board of Directors, has identified and implemented steps to remediate the material weakness.
The Company began implementing the remediation plan during the second quarter of fiscal year 2023 and this remediation is ongoing as of the filing date of this Quarterly Report. The following remedial measures are designed to address the material weakness and to continue to improve our internal control over financial reporting.
| ● | We have engaged external tax advisors to complement internal resources and efforts and provide support in assessing the appropriate sales tax treatment associated with the Company’s products for all prior years in which the Company had generated revenue. |
35
| ● | We have begun obtaining sales tax exemption letters, representation letters or proof of payments of compensating use tax from our customers and we have started a collection effort of these sales taxes from certain customers who have notified the Company that they do not have a sales tax exemption letter. |
| ● | We have begun implementing a sales tax software platform solution for the calculation, collection, and remittance of sales tax for all non-exempt future sales, and assisting with the collection and tracking of Voluntary Disclosure Agreements received from states where a potential sales tax liability may exist. |
| ● | We have begun designing and implementing enhanced policies, procedures and controls related to the calculation, communication, collection, and remittance of sales tax to relevant jurisdictions. |
| ● | We have begun training appropriate personnel in the effective design and execution of our enhanced policies, procedures, and controls, including the importance of the ongoing, consistent effective execution of such procedures and controls. |
We are committed to the remediation of the material weakness and expect to successfully implement enhanced control processes. However, as we continue to evaluate, and work to improve our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. Therefore, we cannot assure you when we will be able to fully remediate such weakness, nor can we be certain that additional actions will not be required or what the costs may be of any such additional actions. Moreover, we cannot assure you that additional material weaknesses will not arise in the future.
Changes in Internal Control Over Financial Reporting
We are in the process of implementing certain changes to our internal controls to remediate the material weakness described above. During the fourth quarter of 2024, the Company underwent leadership transitions at the director and officer levels. To mitigate any risks associated with these changes, the Board has increased its oversight of company payments and financial transactions. Except as noted above, there were no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
36
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
To the knowledge of our management team, there is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, other than the matter described below. We may from time to time be involved in various legal proceedings and other matters arising in the normal course of business. We may in the future institute additional legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.
Focus Technology Solutions, Inc. v. iSpecimen,; Suffolk (MA) Superior Court
On December 9, 2024, Focus Technologies, Inc. (“Focus”) filed a complaint against the Company in the Superior Court of Suffolk County, Massachusetts, alleging non-payment under agreements dated July 29, 2022, related to the provision of information technology services. Focus is seeking approximately $489,572 in damages, plus interest and attorneys’ fees. Following the filing, Focus disabled the Company’s web-based commerce platform on January 24, 2025, resulting in a shutdown of the iSpecimen Marketplace from January 25, 2025, through February 12, 2025, which was not fully resolved until early March 2025.
To restore service, the parties entered into a settlement agreement on February 11, 2025 (the “Settlement Agreement”), under which the Company agreed to pay $500,000 in nine monthly installments in exchange for the restoration of its platform. The Company made an initial payment of $50,000 on February 12, 2025, however, Focus failed to fully restore the platform, requiring the Company to engage a third-party developer to complete the work in early March 2025. On February 28, 2025, the Company notified Focus that it was in breach of the Settlement Agreement and has since withheld further payments thereunder.
Focus amended its complaint to enforce the Settlement Agreement and obtained an order for pre-judgment security in the amount of $420,000, to be funded by 15% of “revenue.” This order was clarified on December 17, 2025 to require only 15% of “net revenue,” with the result only $13,000 has been deposited in escrow to date. The Company has asserted counterclaims against Focus for consequential damages arising from the February 2025 service disruption and failure to perform under the agreements. On September 3, 2025, Focus reduced their global settlement demand to $100,000, and on September 9, 2025, the Company increased their offer to $30,000, which figure was rejected by Focus. The case remains in the discovery phase, and no trial date has been set.
While the outcome of this matter cannot be predicted with certainty, the Company does not believe that this litigation will have a material adverse effect on its business, financial condition, or results of operations at this time.
Azenta US, Inc. v. iSpecimen, Inc.; Suffolk (MA) Superior Court
On or around January 15, 2025, Azenta initiated a claim against the Company for $651,262 arising from an alleged breach of contract, and unjust enrichment. Azenta provided sequencing services in 2023 as part of an initiative for which a market was never realized by the Company. The Company believes that it has valid defenses to Azenta’s claims. Discovery has closed in this case, and the Company expects Azenta to move for summary judgment, which the Company will defend vigorously. As of current, the Company has made an offer of $125,000 to settle this case, but no response has been received from Azenta.
37
Krisbio, LLC v. iSpecimen, Inc.
On or about September 23, 2025 the Company was served with a Summons and Complaint in the matter of Krisbio, LLC v. iSpecimen, Inc. 1:25-CV-12409-JCB in the U.S. District Court for the District of Massachusetts seeking collection of $266,380, alleging breach of contract and other quasi-contractual claims relating to a purported “Participation Agreement” dated July 20, 2021, and subsequent agreements for payments for goods and services under said Participation Agreement. The Company has answered the Complaint, and Initial disclosures have been filed by the parties, but formal discovery has not yet begun.
Ellenoff Grossman & Schole, LLP v. iSpecimen, Inc.; New York County Supreme Court
On or around November 14, 2024, EGS initiated a claim against the Company for $425,684 arising from a breach of contract, and compensation on a quantum meruit basis amongst other things. The Company believes that EGS’ claims are without legal or factual basis, and intends to vigorously defend these claims.
During the three months ended March 31, 2026, the Company settled this legal matter and the parties agreed to a $200,000 settlement pursuant to a settlement agreement executed on February 15, 2026 (Note 14).
Item 1A. Risk Factors.
There have been no material changes with respect to risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 1, 2026.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not Applicable.
Item
5.
On February 17, 2026, Ms. Siyun Yang resigned as a director of the Company, effective immediately. Ms. Yang’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Ms. Yang had served as an independent director since February 2025 and was a member of the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors.
38
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.
| * | Filed herewith. |
| ** | Furnished. |
39
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| iSpecimen Inc. | ||
| Date: May 15, 2026 | By: | /s/ Katharyn Field |
| Name: | Katharyn Field | |
| Title: | Chief
Executive Officer, President, (Principal Executive Officer) | |
40
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Katharyn Field, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of iSpecimen Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 15, 2026 | |
| /s/ Katharyn Field | |
| Katharyn Field | |
| Chief Executive Officer | |
| (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Yuying Liang, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of iSpecimen Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 15, 2026
| /s/ Yuying Liang | |
| Yuying Liang | |
| Chief Financial Officer | |
| (Principal Accounting and Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of iSpecimen Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the “Report”), I, Katharyn Field, Chief Executive Officer, President, Secretary and Treasurer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report. |
| Date: May 15, 2026 | |
| /s/ Katharyn Field | |
| Katharyn Field | |
| Chief Executive Officer, Secretary and Treasurer | |
| (Principal Executive Officer) |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of iSpecimen Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the “Report”), I, Yuying Liang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report. |
| Date: May 15, 2026 | |
| /s/ Yuying Liang | |
| Yuying Liang | |
| Chief Financial Officer | |
| (Principal Financial Officer) |